在患有镰状细胞病的儿科患者中，阿仑单抗治疗和造血细胞移植后发生的自身免疫性甲状腺疾病。
Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.
作者信息
Williams Kristen M, Dietzen Danielle, Hassoun Abeer A, Fennoy Ilene, Bhatia Monica
机构信息
Department of Pediatrics, Columbia University Medical Center, New York, NY.
出版信息
Pediatr Blood Cancer. 2014 Dec;61(12):2307-9. doi: 10.1002/pbc.25102. Epub 2014 Jun 17.
Abstract
Allogenic hematopoietic cell transplantation (alloHCT) is currently the only curative treatment option for patients with sickle cell disease. Alemtuzumab is a monoclonal antibody directed against CD52 positive cells used in myeloablative conditioning regimens for alloHCT. Its use has been associated with development of autoimmune disease in adult patients with rheumatologic conditions. We report on three cases of new onset autoimmune thyroid disease after alloHCT treatment with alemtuzumab in pediatric patients with sickle cell disease.
摘要
异基因造血细胞移植（alloHCT）目前是镰状细胞病患者唯一的治愈性治疗选择。阿仑单抗是一种针对CD52阳性细胞的单克隆抗体，用于alloHCT的清髓性预处理方案。在患有风湿性疾病的成年患者中，其使用与自身免疫性疾病的发生有关。我们报告了3例镰状细胞病儿科患者在接受阿仑单抗alloHCT治疗后新发自身免疫性甲状腺疾病的病例。
相似文献
1
Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.在患有镰状细胞病的儿科患者中，阿仑单抗治疗和造血细胞移植后发生的自身免疫性甲状腺疾病。
Pediatr Blood Cancer. 2014 Dec;61(12):2307-9. doi: 10.1002/pbc.25102. Epub 2014 Jun 17.
2
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.非清髓性 HLA 匹配同胞供体异基因造血干细胞移植治疗严重镰状细胞表型。
JAMA. 2014 Jul 2;312(1):48-56. doi: 10.1001/jama.2014.7192.
3
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.异体造血干细胞移植治疗镰状细胞病。
N Engl J Med. 2009 Dec 10;361(24):2309-17. doi: 10.1056/NEJMoa0904971.
4
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.镰状细胞病患儿采用白消安、氟达拉滨、阿仑单抗进行减毒清髓预处理及同胞供体造血干细胞移植的毒性降低情况。
Bone Marrow Transplant. 2014 Jul;49(7):913-20. doi: 10.1038/bmt.2014.84. Epub 2014 May 5.
5
Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.阿仑单抗给药时机与骨髓输注日的关系及其对镰状细胞病患者植入和移植物抗宿主病的影响：一项单机构研究。
J Pediatr Hematol Oncol. 2020 Nov;42(8):e718-e722. doi: 10.1097/MPH.0000000000001930.
6
Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.降低强度调节性异基因造血细胞移植中阿仑单抗的剂量与早期强烈的自然杀伤细胞恢复有关。
Cytotherapy. 2013 Oct;15(10):1237-44. doi: 10.1016/j.jcyt.2013.05.016.
7
Graves' disease after treatment with alemtuzumab for multiple sclerosis.多发性硬化症用阿仑单抗治疗后发生格雷夫斯病。
Hormones (Athens). 2015 Jan-Mar;14(1):148-53. doi: 10.14310/horm.2002.1501.
8
Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.使用阿仑单抗/低剂量放疗进行非清髓性干细胞移植以治愈并改善镰状细胞病成人患者的生活质量
Biol Blood Marrow Transplant. 2016 Mar;22(3):441-8. doi: 10.1016/j.bbmt.2015.08.036. Epub 2015 Sep 5.
9
Reconsideration of age as a contraindication for curative therapy of sickle cell disease.重新审视年龄作为镰状细胞病根治性治疗禁忌证的问题。
JAMA. 2014 Jul 2;312(1):33-4. doi: 10.1001/jama.2014.7193.
10
Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease.镰状细胞病非清髓性干细胞移植后每月使用利妥昔单抗成功治疗难治性自身免疫性溶血性贫血。
J Pediatr Hematol Oncol. 2004 May;26(5):312-4. doi: 10.1097/00043426-200405000-00011.
引用本文的文献
1
Thyroid and Adrenal Dysfunction in Hemoglobinopathies Before and After Allogeneic Hematopoietic Cell Transplant.异基因造血细胞移植前后血红蛋白病中的甲状腺和肾上腺功能障碍
J Endocr Soc. 2023 Oct 31;7(12):bvad134. doi: 10.1210/jendso/bvad134. eCollection 2023 Nov 2.
2
Adrenal crisis in a 14-year-old boy 12 years after hematopoietic stem cell transplantation.造血干细胞移植12年后一名14岁男孩发生肾上腺危象。
Endocrinol Diabetes Metab Case Rep. 2018 Jun 6;2018. doi: 10.1530/EDM-18-0034. eCollection 2018.
3
Graves' orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy?范可尼贫血患者异基因骨髓移植后发生格雷夫斯眼眶病——是阿仑单抗治疗的副作用吗？
Clin Case Rep. 2018 Mar 12;6(5):867-870. doi: 10.1002/ccr3.1486. eCollection 2018 May.
4
Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.接受阿仑单抗治疗的多发性硬化症患者的自身免疫性甲状腺疾病：选择性抗促甲状腺激素受体免疫反应的一个实例
Front Endocrinol (Lausanne). 2017 Sep 28;8:254. doi: 10.3389/fendo.2017.00254. eCollection 2017.
本文引用的文献
1
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.镰状细胞病患儿采用白消安、氟达拉滨、阿仑单抗进行减毒清髓预处理及同胞供体造血干细胞移植的毒性降低情况。
Bone Marrow Transplant. 2014 Jul;49(7):913-20. doi: 10.1038/bmt.2014.84. Epub 2014 May 5.
2
Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.在多发性硬化症中使用阿仑单抗治疗自身免疫性甲状腺疾病：综述。
Endocr Pract. 2013 Sep-Oct;19(5):821-8. doi: 10.4158/EP13020.RA.
3
Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling.血红蛋白病患者接受 HLA 相同同胞来源的脐带血或骨髓移植的结果。
Blood. 2013 Aug 8;122(6):1072-8. doi: 10.1182/blood-2013-03-489112. Epub 2013 May 21.
4
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.白消安、氟达拉滨和阿仑单抗预处理及无关脐血移植治疗镰状细胞病患儿
Biol Blood Marrow Transplant. 2013 Apr;19(4):676-7. doi: 10.1016/j.bbmt.2013.02.002. Epub 2013 Feb 9.
5
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.阿仑单抗与干扰素β1a 作为复发缓解型多发性硬化症一线治疗的比较：一项随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.
6
Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.多发性硬化症用阿仑单抗治疗后的继发性自身免疫性疾病。
Expert Rev Neurother. 2012 Mar;12(3):335-41. doi: 10.1586/ern.12.5.
7
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.多发性硬化症患者接受阿仑单抗治疗后的淋巴细胞长期重建。
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304. doi: 10.1136/jnnp-2011-300826. Epub 2011 Nov 5.
8
Endocrine complications following pediatric bone marrow transplantation.儿童骨髓移植后的内分泌并发症。
J Pediatr Endocrinol Metab. 2011;24(5-6):327-32. doi: 10.1515/jpem.2011.021.
9
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.多发性硬化症患者用阿仑单抗治疗后的自身免疫性疾病：一项多中心队列研究。
Neurology. 2011 Aug 9;77(6):573-9. doi: 10.1212/WNL.0b013e318228bec5. Epub 2011 Jul 27.
10
Immune reconstitution syndrome and the thyroid.免疫重建综合征与甲状腺。
Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):693-702. doi: 10.1016/j.beem.2009.07.003.
Zotero 插件